Back to top

Analyst Blog

On Apr 3, Zacks Investment Research downgraded Echo Therapeutics, Inc. (ECTE - Snapshot Report) to a Zacks Rank #4 (Sell).

Why the Downgrade?

This Philadelphia-based developer of transdermal skin permeation and diagnostic medical devices reported its fourth-quarter and full-year 2013 results on Mar 27. The fourth-quarter reported loss per share more than doubled year over year to $3.9 million or 36 cents. However, adjusted loss per share of 35 cents was narrower than the Zacks Consensus Estimate of a loss of 36 cents.

Echo Therapeutics' selling, general and administrative (SG&A) expenses scaled up 31.3% to $8.4 million during 2013. Factors like increased personnel costs, legal costs and expenses related to prelaunch marketing and manufacturing activities contributed to this hike in SG&A expenses.
In addition, the company's research and development (R&D) expenses for 2013 also increased 29.9% year over year to $11.3 million. This rise was primarily driven by increased engineering and design expenses incurred on account of outside contracts and personnel relating to the Symphony development. As a result of higher R&D and SG&A expenses, Echo Therapeutics saw a 31% year-over-year increase in operating loss to $19.6 million in 2013.

Given broad market fluctuations that have already adversely affected the market price of Echo Therapeutics' common stock, management has announced that the company's stock price is volatile at present and has every possibility to fluctuate in the near future.

The Zacks Consensus Estimate of a loss for 2014 has rose 7.7% to 98 cents per share over the last 30 days. However, for 2015, the Zacks Consensus Estimate of a loss remained flat at $1.07 over the same period.

Other Stocks to Consider

Investors interested in the Medical Instruments space may consider better-ranked stocks like Cynosure, Inc. (CYNO - Snapshot Report), Delcath Systems, Inc. and Syneron Medical Ltd. (ELOS - Snapshot Report). All these stocks carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%